Preoperative Dialysis Dose and Postoperative Outcomes in Patients Receiving Maintenance Hemodialysis.

IF 3.2 Q1 UROLOGY & NEPHROLOGY
Kidney360 Pub Date : 2025-06-12 DOI:10.34067/KID.0000000874
Vikram Fielding-Singh, Matthew W Vanneman, Arden M Morris, Wolfgang C Winkelmayer, Louise Y Sun, Pavel S Roshanov, Maria Montez-Rath, Glenn M Chertow, Eugene Lin
{"title":"Preoperative Dialysis Dose and Postoperative Outcomes in Patients Receiving Maintenance Hemodialysis.","authors":"Vikram Fielding-Singh, Matthew W Vanneman, Arden M Morris, Wolfgang C Winkelmayer, Louise Y Sun, Pavel S Roshanov, Maria Montez-Rath, Glenn M Chertow, Eugene Lin","doi":"10.34067/KID.0000000874","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Little is known about preoperative hemodialysis dosing for patients with end-stage kidney disease. We assessed whether changes in preoperative hemodialysis dose (compared to and controlling for baseline dose) are associated with postoperative mortality in patients receiving maintenance hemodialysis.</p><p><strong>Methods: </strong>We identified fee-for-service Medicare beneficiaries receiving hemodialysis for end-stage kidney disease who underwent surgical procedures between January 1, 2011, and November 30, 2020. Follow-up ended December 31, 2020. The primary exposure was preoperative change in Kt/Vurea, defined as the difference between the Kt/Vurea in the hemodialysis session proximal to the procedure and the mean Kt/Vurea for the preceding 180 days. The primary outcome was postoperative 30-day mortality. The relation between preoperative change in Kt/Vurea and the primary outcome was modeled using a Cox proportional hazards regression model, adjusted for mean and standard deviation of Kt/Vurea in the 180 days preceding the procedure, and for other covariates.</p><p><strong>Results: </strong>Among 151,240 procedures (median age, 65 years [25%-75% range, 56-73], 63,437 (41.9%) in women), 31,825 (21.0%) had a preoperative change in Kt/Vurea of <-0.10, 43,790 (29.0%) had a preoperative change of -0.10 to < 0, 45,058 (29.8%) had a preoperative change of 0 to <+0.10, and 30,567 (20.2%) had a preoperative change of ≥+0.10. The median Kt/Vurea for the 180 days prior to the procedure was 1.58 (25th-75th percentiles, 1.45-1.74). In adjusted analysis, compared to patients with a preoperative change in Kt/Vurea of 0 to <+0.10, 30-day mortality was 1.50 (95% CI, 1.32, 1.70) times higher with a preoperative Kt/Vurea change of ≤-0.10 and 1.16 (95% CI, 1.02, 1.31) times higher with a preoperative Kt/Vurea change of -0.10 to < 0. Increases in preoperative Kt/Vurea that were greater than 0.10 were not significantly associated with 30-day mortality.</p><p><strong>Conclusions: </strong>Among Medicare beneficiaries receiving maintenance hemodialysis, preoperative decreases in Kt/Vurea (compared to and controlling for mean Kt/Vurea) were significantly associated with postoperative mortality.</p>","PeriodicalId":17882,"journal":{"name":"Kidney360","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34067/KID.0000000874","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Little is known about preoperative hemodialysis dosing for patients with end-stage kidney disease. We assessed whether changes in preoperative hemodialysis dose (compared to and controlling for baseline dose) are associated with postoperative mortality in patients receiving maintenance hemodialysis.

Methods: We identified fee-for-service Medicare beneficiaries receiving hemodialysis for end-stage kidney disease who underwent surgical procedures between January 1, 2011, and November 30, 2020. Follow-up ended December 31, 2020. The primary exposure was preoperative change in Kt/Vurea, defined as the difference between the Kt/Vurea in the hemodialysis session proximal to the procedure and the mean Kt/Vurea for the preceding 180 days. The primary outcome was postoperative 30-day mortality. The relation between preoperative change in Kt/Vurea and the primary outcome was modeled using a Cox proportional hazards regression model, adjusted for mean and standard deviation of Kt/Vurea in the 180 days preceding the procedure, and for other covariates.

Results: Among 151,240 procedures (median age, 65 years [25%-75% range, 56-73], 63,437 (41.9%) in women), 31,825 (21.0%) had a preoperative change in Kt/Vurea of <-0.10, 43,790 (29.0%) had a preoperative change of -0.10 to < 0, 45,058 (29.8%) had a preoperative change of 0 to <+0.10, and 30,567 (20.2%) had a preoperative change of ≥+0.10. The median Kt/Vurea for the 180 days prior to the procedure was 1.58 (25th-75th percentiles, 1.45-1.74). In adjusted analysis, compared to patients with a preoperative change in Kt/Vurea of 0 to <+0.10, 30-day mortality was 1.50 (95% CI, 1.32, 1.70) times higher with a preoperative Kt/Vurea change of ≤-0.10 and 1.16 (95% CI, 1.02, 1.31) times higher with a preoperative Kt/Vurea change of -0.10 to < 0. Increases in preoperative Kt/Vurea that were greater than 0.10 were not significantly associated with 30-day mortality.

Conclusions: Among Medicare beneficiaries receiving maintenance hemodialysis, preoperative decreases in Kt/Vurea (compared to and controlling for mean Kt/Vurea) were significantly associated with postoperative mortality.

维持性血液透析患者的术前透析剂量和术后预后。
背景:对于终末期肾病患者的术前血液透析剂量知之甚少。我们评估了术前血液透析剂量的变化(与基线剂量相比)是否与接受维持性血液透析患者的术后死亡率相关。方法:我们确定了在2011年1月1日至2020年11月30日期间接受终末期肾病血液透析手术的按服务收费的医疗保险受益人。后续调查于2020年12月31日结束。主要暴露是术前Kt/ v尿素的变化,定义为手术近端血液透析阶段Kt/ v尿素与前180天平均Kt/ v尿素之间的差异。主要终点为术后30天死亡率。术前Kt/Vurea变化与主要结局之间的关系采用Cox比例风险回归模型进行建模,并根据术前180天Kt/Vurea的平均值和标准差以及其他协变量进行调整。结果:在151,240例手术(中位年龄为65岁[25%-75%范围,56-73])中,63,437例(41.9%)为女性),31,825例(21.0%)术前Kt/ v尿素发生变化。结论:在接受维持性血液透析的医疗保险受益人中,术前Kt/ v尿素降低(与平均Kt/ v尿素相比并控制平均Kt/ v尿素)与术后死亡率显著相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney360
Kidney360 UROLOGY & NEPHROLOGY-
CiteScore
3.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信